Hi @Taureanbull, Great post. My view of the Webinar is overall positive, all 3 participantswere open, honest and across their brief.That doesn’t mean that there weren’t any areas of the discussionsthat didn’t concern me.
For example, PH spoke of the overall success rate of small biotechcompanies, the very low percentage of approved drugs that became commercial demonstratesthe huge uphill battle we are invested in.
I have been somewhat aware of this information, but having itcome from him was a hard swallow. Having said that, they must have some confidencethat they have really good IP, otherwise why would they invest in such a big wayto try and find a successful treatment for cancer.
Also the 2-3 year timeline on Azer-cel for a registrational trialseemed to contradict what Leslie had been hinting at in previous investor communications,although being made aware that CAR-T’s only need Ph2 for approval did somewhat softenthis blow.
The shareprice was addressed in great detail and as PH admittedthey are all at a loss as to how it can be so low given the excellent results (4CRs in Azer-cel trial) they have achieved.
Raising the spectre of short sellingas also contributing and spurring other sellers to react to the short level helpsto explain the sp decline.However what is clear is that they believe with what they havein the way of IP and with their strong Leadership the share price should be realisticallymuch higher.
We were certainly brought back down to earth with the soberinginformation regarding how difficult and painfully slow results take to show themselvesin these trials, along with the huge costs.
I believe further slowing of the MAST trial will be confirmedas $ start to run down towards the end of the year, with the OASIS trial becomingthe priority to show CD19 shuttling to the surface of solid tumours. Evidence of this will certainly encourage further interest fromblood cancer drug companies.
Azer-cel is the main game, with further trial sites and otherindications expanding the potential for BP interest, unfortunately this also appearsto be the biggest drain on available funds.
So, in summary, content that I have made a potentially greatinvestment, not without risk but with confidence better times are not far away.
DYOR opinion only
IMU Price at posting:
2.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)